October 12, 2017Osteoarthritis and CartilageOpen Access

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA)

View Full Paper

Ask AI

Bookmark

Abstract

In knee OA patients, microsphere-based TA delivery via a single IA injection prolonged SF joint residency, diminished peak plasma levels, and thus reduced systemic TA exposure relative to TAcs.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kraus et al. (2017) studied this question.

synapsesocial.com/papers/69d9d9d95e5bcb4e3b838107 https://doi.org/10.1016/j.joca.2017.10.003

View Full Paper

Ask AI

Bookmark

Abstract

In knee OA patients, microsphere-based TA delivery via a single IA injection prolonged SF joint residency, diminished peak plasma levels, and thus reduced systemic TA exposure relative to TAcs.

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA)

Abstract

Discussion

Cite This Study

Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA)

Abstract

Discussion

Cite This Study

Keep reading

Keep reading